Phillip D. Toth

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom, Tomas Hala, Michael A. Bolognese et al. · New England Journal of Medicine · 2014 · 700 citations · Full text

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

Harold Bays, Paul B. Moore, Margaret Drehobl et al. · Clinical Therapeutics · 2001 · 311 citations

Primary Hypercholesterolemia, Cardiovascular Disease, Hyperlipidemia +5

Colesevelam Hydrochloride (Cholestagel)

Michael H. Davidson, Maureen Dillon, Bruce R. Gordon et al. · Archives of Internal Medicine · 1999 · 306 citations

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix.

Moti L. Kashyap, Mark E. McGovern, Kathleen Berra et al. · The American Journal of Cardiology · 2002 · 234 citations

Drug Safety, Cardiovascular Disease, Medicine +6

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9